Andrea Mafficini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5970778/publications.pdf

Version: 2024-02-01

79 papers	4,329 citations	147801 31 h-index	110387 64 g-index
80 all docs	80 docs citations	80 times ranked	7196 citing authors

#	Article	IF	Citations
1	Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut, 2022, 71, 961-973.	12.1	60
2	Molecular Analysis of an Intestinal Neuroendocrine/Non-neuroendocrine Neoplasm (MiNEN) Reveals MLH1 Methylation-driven Microsatellite Instability and a Monoclonal Origin: Diagnostic and Clinical Implications. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 145-152.	1.2	5
3	Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1261-1268.	2.8	12
4	Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants. Familial Cancer, 2022, 21, 441-451.	1.9	3
5	Recurrent oligodendroglioma with changed 1p/19q status. Neuropathology, 2022, , .	1.2	3
6	Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. Expert Opinion on Therapeutic Targets, 2022, 26, 1-4.	3.4	5
7	â€œPureâ€•hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 41-47.	2.8	6
8	Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. Modern Pathology, 2022, 35, 712-720.	5.5	17
9	Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. Human Pathology, 2022, 128, 124-133.	2.0	6
10	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut, 2021, 70, 1904-1913.	12.1	24
11	Molecular Biology of Neuroendocrine Tumors. , 2021, , 37-53.		0
12	DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 2021, 4, 155.	4.4	26
13	Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different BRCA2 Germline Mutations: New Horizons from Tumor Molecular Profiling. Genes, 2021, 12, 481.	2.4	13
14	Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades. Cancers, 2021, 13, 2054.	3.7	10
15	Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers, 2021, 13, 3119.	3.7	69
16	Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extranodal extension influences disease-free survival. Pathology Research and Practice, 2021, 224, 153519.	2.3	7
17	Genomic characterization of hepatoid tumors: context matters. Human Pathology, 2021, 118, 30-41.	2.0	9
18	IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. Acta Neuropathologica Communications, 2021, 9, 200.	5.2	10

#	Article	IF	Citations
19	Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles. Expert Opinion on Therapeutic Targets, 2021, 25, 1095-1105.	3.4	13
20	Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases. Annals of Oncology, 2019, 30, v574.	1.2	0
21	Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. Cancers, 2019, 11, 1279.	3.7	23
22	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. Journal of Thoracic Oncology, 2019, 14, 1651-1661.	1.1	73
23	Comparative Lesions Analysis Through a Targeted Sequencing Approach. Journal of Visualized Experiments, 2019, , .	0.3	0
24	P2.04-51 A 6-Gene Immune Genomic Signature (IGS) Predicts Resistance to Nivolumab [NIV] in Advanced Pretreated NSCLC: Results of PRINCiPe Trial. Journal of Thoracic Oncology, 2019, 14, S728.	1.1	0
25	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma. Pancreas, 2019, 48, 70-76.	1.1	11
26	Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas. Journal of Pathology, 2019, 247, 123-134.	4.5	32
27	Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocrine Reviews, 2019, 40, 506-536.	20.1	146
28	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 567-577.	2.8	64
29	Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium. Journal of Endocrinology, 2018, 236, R161-R167.	2.6	79
30	Ampulla of Vater Carcinoma. Annals of Surgery, 2018, 267, 149-156.	4.2	35
31	Non-coding regulatory variations: the dark matter of pancreatic cancer genomics. Gut, 2018, 67, 399-400.	12.1	3
32	P2.04-12 A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.. Journal of Thoracic Oncology, 2018, 13, S734-S735.	1.1	0
33	Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 709-717.	2.8	40
34	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. Pathology Research and Practice, 2018, 214, 1675-1680.	2.3	1
35	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. Carcinogenesis, 2018, 39, 971-980.	2.8	48
36	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. Human Pathology, 2018, 81, 157-165.	2.0	44

#	Article	IF	Citations
37	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Scientific Reports, 2018, 8, 7119.	3.3	39
38	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. BMC Cancer, 2018, 18, 828.	2.6	19
39	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	27.8	716
40	Splice variants as novel targets in pancreatic ductal adenocarcinoma. Scientific Reports, 2017, 7, 2980.	3.3	34
41	OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). Journal of Thoracic Oncology, 2017, 12, S266-S267.	1.1	4
42	Fhit down-regulation is an early event in pancreatic carcinogenesis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 647-653.	2.8	5
43	Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. Annals of Oncology, 2017, 28, 1243-1249.	1.2	25
44	Pancreatic undifferentiated carcinoma with osteoclastâ€like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. Journal of Pathology, 2017, 243, 148-154.	4.5	79
45	A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type Î³ in chronic myeloid leukemia patients. Journal of Hematology and Oncology, 2017, 10, 129.	17.0	17
46	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatinâ€remodelling genes as major players and a prognostic role for <scp>TERT</scp>, <scp>RB1</scp>, <scp>MEN1</scp> and <scp>KMT2D</scp>. Journal of Pathology, 2017, 241, 488-500.	4.5	179
47	Abstract 5694: Multi institutional evaluation of a new NGS assay for mutation detection from cfDNA in lung cancer. , 2017, , .		0
48	New genomic landscapes and therapeutic targets for biliary tract cancers. Frontiers in Bioscience - Landmark, 2016, 21, 707-718.	3.0	5
49	CD71 in Gestational Pathology. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 215-220.	1.2	23
50	BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget, 2016, 7, 1076-1083.	1.8	68
51	Specific expression patterns of epithelial to mesenchymal transition factors in gestational molar disease. Placenta, 2015, 36, 1318-1324.	1.5	18
52	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer, 2015, 15, 26.	2.6	49
53	A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discovery, 2015, 5, 1296-1313.	9.4	145
54	Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. Hereditary Cancer in Clinical Practice, 2015, 13, 18.	1.5	31

#	Article	IF	Citations
55	Abstract 4891: Comprehensive genetic profiling of chromosomal translocations in lung cancer tumors: development and validation of a next-generation sequencing panel in an international multicenter study. , 2015, , .		0
56	Impact of MIF Gene Promoter Polymorphism on F508del Cystic Fibrosis Patients. PLoS ONE, 2014, 9, e114274.	2.5	7
57	Targeted nextâ€generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. Journal of Pathology, 2014, 233, 217-227.	4.5	308
58	Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma. Journal of Clinical Oncology, 2014, 32, e63-e66.	1.6	47
59	Mixed Adenoneuroendocrine Carcinomas of the Gastrointestinal Tract: Targeted Next-Generation Sequencing Suggests a Monoclonal Origin of the Two Components. Neuroendocrinology, 2014, 100, 310-316.	2.5	115
60	High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer, 2014, 17, 442-449.	5.3	52
61	High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 73-78.	2.8	66
62	Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel. Cancer Research, 2014, 74, 3575-3575.	0.9	4
63	Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis. PLoS ONE, 2014, 9, e104979.	2.5	35
64	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget, 2014, 5, 2839-2852.	1.8	171
65	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genetics, 2013, 45, 1470-1473.	21.4	564
66	ICAT is a novel Ptf1a interactor that regulates pancreatic acinar differentiation and displays altered expression in tumours. Biochemical Journal, 2013, 451, 395-405.	3.7	6
67	DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples. PLoS ONE, 2013, 8, e62692.	2.5	209
68	Pancreatic Cancer Genomics. , 2013, , 219-253.		1
69	Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel. PLoS ONE, 2013, 8, e80478.	2.5	96
70	Impact of polymorphism of Multidrug Resistance-associated Protein 1 (ABCC1) gene on the severity of cystic fibrosis. Journal of Cystic Fibrosis, 2011, 10, 228-233.	0.7	7
71	Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer, 2011, 11, 448.	2.6	35
72	Immunohistochemical detection of arginine methylated proteins (MeRP) in archival tissues. Histopathology, 2010, 57, 725-733.	2.9	7

#	Article	IF	Citations
73	Protein Tyrosine Phosphatase Receptor Type Î³ Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia. Cancer Research, 2010, 70, 8896-8906.	0.9	46
74	Protein Tyrosine Phosphatase Gamma (PTPÎ³) is a Novel Leukocyte Marker Highly Expressed by CD34+ Precursors. Biomarker Insights, 2007, 2, 117727190700200.	2.5	9
75	Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts. Cancer Gene Therapy, 2007, 14, 781-790.	4.6	8
76	Expression of transmembrane protein tyrosine phosphatase gamma (PTP?) in normal and neoplastic human tissues. Histopathology, 2007, 50, 615-628.	2.9	28
77	Protein Tyrosine Phosphatase Gamma (PTPgamma) is a Novel Leukocyte Marker Highly Expressed by CD34 Precursors. Biomarker Insights, 2007, 2, 218-25.	2.5	7
78	Receptor-type protein tyrosine phosphatase gamma (PTPÎ³), a new identifier for myeloid dendritic cells and specialized macrophages. Blood, 2006, 108, 4223-4231.	1.4	16
79	Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB Journal, 2005, 19, 1125-1127.	0.5	122